Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT2 Inhibitors for No-reflow Phenomenon in Myocardial Infarction Undergoing PCI
NCT07898709Phase 2Not yet recruiting
- Sponsor
- Al-Azhar University
- Start
- Jan 2027
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
A Phase 2 trial of empagliflozin, dapagliflozin in myocardial infarction (MI), no-reflow phenomenon, sponsored by Al-Azhar University. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
empagliflozindapagliflozin
03
Conditions
myocardial infarction (MI)no-reflow phenomenon
Beyond the preview
Go deeper on NCT07898709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07898709.